



## Saurabh Dahiya, MD, FACP

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

### CLINICAL OFFICES

- **Blood and Marrow Transplant Program**

300 Pasteur Dr Rm H0101

MC 5623

Stanford, CA 94305

**Tel** (650) 724-4155      **Fax** (650) 498-6919

### Bio

---

#### BIO

Dr. Dahiya is a cancer specialist with board certification in internal medicine, hematology, and medical oncology. He is an Associate Professor at Stanford University School of Medicine and Clinical Director of Cancer Cell Therapy in the Stanford BMT and Cell Therapy division.

Dr. Dahiya strives to support each patient with a personalized and compassionate care plan that optimizes healing and quality of life.

Prior to joining Stanford, Dr. Dahiya was an associate professor of medicine at the Greenebaum Comprehensive Cancer Center at the University of Maryland School of Medicine, where he developed the Cellular Immunotherapy Program and served as the Director of Cellular Immunotherapy in leukemia and lymphoma.

Dr. Dahiya's research focuses on cellular immunotherapy for hematologic malignancies. He has led and participated in several investigator-initiated studies and sponsored clinical trials with cell therapies (CAR-T, CAR-NK, TCR-T) for hematologic malignancies. His research group is also involved in various translational research activities for the standard of care and research CAR-T therapy. Dr. Dahiya's group was the first group to show the role of fibrinogen in Neurotoxicity associated with CAR-T therapy. They showed vascular injury as manifested by high fibrinogen levels is associated with higher Neurotoxicity in patients who receive CAR-T therapy. More recently his group led a novel study of assessing the immune response to COVID-19 disease. They evaluated the immune response in critically ill and non-critically ill patients hospitalized with COVID-19 disease and showed a differential immune response between the groups. Dr. Dahiya's group also showed and established poor immunogenicity of COVID-19 vaccines in CART recipients. As such, passive immunity and other strategies to address the issues of immunogenicity are being explored.

He has published more than 50 articles in peer-reviewed journals including the New England Journal of Medicine, Journal of Clinical Oncology, Blood, Blood Advances, Lancet, Leukemia Research, Neuro-Oncology, and many more. He reviews article submissions for the journals Critical Reviews in Oncology and Hematology, Thoracic Cancer, and Blood. He serves as the hematology lead editor for the journal Critical Reviews in Oncology and Hematology.

He has presented his research findings at conferences such as the annual meetings of the American Society of Hematology, American Society of Clinical Oncology, and American Society for Transplantation and Cell Therapy.

Dr. Dahiya is a member of the American Society of Hematology and the American Society of Transplantation and Cell Therapy.

## CLINICAL FOCUS

- Blood and Marrow Transplantation
- Cellular Therapy
- Hematology

## ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Medicine - Blood & Marrow Transplantation

## PROFESSIONAL EDUCATION

- Fellowship: Stanford University Bone Marrow Transplant Fellowship (2017) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2016)
- Board Certification: Hematology, American Board of Internal Medicine (2016)
- Fellowship: Baystate Medical Center (2016) MA
- Fellowship: Cleveland Clinic Graduate Medical Education (2013) OH
- Board Certification: Internal Medicine, American Board of Internal Medicine (2012)
- Residency, Baystate Medical Center/Tufts University School of Medicine , Internal Medicine Residency (2012)
- Internship: Western Reserve Care System (2010) OH
- Medical Education: Maulana Azad Medical College (2008) India

## Research & Scholarship

---

### CLINICAL TRIALS

- Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel, Recruiting
- Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma, Recruiting

## Publications

---

### PUBLICATIONS

- **Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.** *British journal of haematology*  
Gao, J., Dahiya, S., Patel, S. A.  
2023
- **Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy.** *Clinical lymphoma, myeloma & leukemia*  
Lutfi, F., Goloubeva, O., Kowatli, A., Gryaznov, A., Kim, D. W., Dureja, R., Margiotta, P., Matsumoto, L. R., Bukhari, A., Ahmed, N., Mushtaq, M. U., Law, J. Y., Lee, et al  
2023
- **Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).** *Human vaccines & immunotherapeutics*  
Kline, K., Chen, W., Kallen, M. E., Koka, R., Omili, D., Fan, X., Iraguha, T., Gebru, E., Dishanthan, N., Baker, J. M., Dietze, K. A., Yared, J. A., Hankey, et al  
2023: 2216116

- **Survival with Axicabtagene Ciloleucl in Large B-Cell Lymphoma.** *The New England journal of medicine*  
Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M. A., Ghobadi, A., Rapoport, A. P., Sureda, A., Jacobson, C. A., Farooq, U., van Meerten, T., Ulrickson, M., Elsayy, et al  
2023
- **Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucl in Large B-cell Lymphoma.** *Blood advances*  
Dean, E. A., Kimmel, G. J., Frank, M. J., Bukhari, A., Hossain, N. M., Jain, M. D., Dahiya, S., Miklos, D. B., Altrock, P. M., Locke, F. L.  
2023
- **Second-line treatment with CAR T-cell therapy for large B-cell lymphoma.** *Clinical advances in hematology & oncology : H&O*  
Lutfi, F., Patel, A., Mehta, J., Goyal, A., Dahiya, S.  
2023; 21 (4): 170-178
- **Second-line Treatment With CAR T-Cell Therapy for Large B-Cell Lymphoma** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*  
Lutfi, F., Patel, A., Mehta, J., Goyal, A., Dahiya, S.  
2023; 21 (4): 170-178
- **Brexucabtagene Autoleucl for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Wang, Y., Jain, P., Locke, F. L., Maurer, M. J., Frank, M. J., Munoz, J. L., Dahiya, S., Beitinjaneh, A. M., Jacobs, M. T., McGuirk, J. P., Vose, J. M., Goy, A., Andreadis, et al  
2023: JCO2201797
- **Prophylactic Corticosteroid Use with Axicabtagene Ciloleucl (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes**  
Khurana, A., Bailey, M., Iqbal, M., Bansal, R., Lee, C. J., Hunter, B., Lunning, M. A., Jaglowski, S., Jain, M. D., Dahiya, S., Bachanova, V., Farooq, U., Ahmed, et al  
AMER SOC HEMATOLOGY.2022: 4657-4660
- **Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects**  
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamareisis, J., Esfahani, M., Good, Z., Sworder, B., Schroers-Martin, J., Liu, C., Severinsen, F., Hanson, P. J., Lu, Y., Lowsky, et al  
AMER SOC HEMATOLOGY.2022: 7545-7547
- **The Development of Carhlh after Axicabtagene Ciloleucl Is Associated with Poor Outcomes**  
Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentile, C., Mina, A., Arai, S., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, et al  
AMER SOC HEMATOLOGY.2022: 12775-12777
- **Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma**  
Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamareisis, J., Patil, S., Hanson, P. J., Latchford, T., Arai, S., Johnston, L. J., Lowsky, R., Negrin, R. S., Rezvani, A. R., Shizuru, et al  
AMER SOC HEMATOLOGY.2022: 10371-10373
- **A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma**  
Perales, M., Ahmed, S., Dahiya, S., Riedell, P. A., McGuirk, J. P., Oluwole, O. O., Chaudhry, S. A., Lee, Z., Dai, S., Dixit, N., Fanton, C., Marcondes, M. Q., Zalevsky, et al  
AMER SOC HEMATOLOGY.2022: 7488-7490
- **Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucl in second-line large B-cell lymphoma.** *Blood*  
Elsawy, M., Chavez, J. C., Avivi, I., Larouche, J. F., Wannesson, L., Cwynarski, K., Osman, K., Davison, K., Rudzki, J. D., Dahiya, S., Dorritie, K. A., Jaglowski, S. M., Radford, et al  
2022
- **Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy.** *Blood*  
Atanackovic, D., Luetkens, T., Omili, D., Iraguha, T., Lutfi, F., Hardy, N. M., Fan, X., Avila, S. V., Saharia, K. K., Husson, J. S., Niederhaus, S. V., Margiotta, P., Lee, et al  
2022; 140 (2): 152-156

- **T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine.** *Journal for immunotherapy of cancer*  
Atanackovic, D., Kreitman, R. J., Cohen, J., Hardy, N. M., Omili, D., Iraguha, T., Burbelo, P. D., Gebru, E., Fan, X., Baddley, J., Luetkens, T., Dahiya, S., Rapoport, et al  
2022; 10 (7)
- **KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).**  
Nastoupil, L. J., Dahiya, S., Miklos, D., Reagan, P., Ulrickson, M., Jung, A., Kloos, I., Dong, J., Chou, J., Murakami, J., Rodriguez, K., Nahas, M.  
LIPPINCOTT WILLIAMS & WILKINS.2022
- **The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.** *Clinical lymphoma, myeloma & leukemia*  
Nuvvula, S., Dahiya, S., Patel, S. A.  
2022; 22 (6): 362-372
- **Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.** *Leukemia & lymphoma*  
Kim, D. W., Bukhari, A., Lutfi, F., Zaffaroni, F., Merechi, F., Mustafa Ali, M. K., Gottlieb, D., Lee, S. T., Kocoglu, M. H., Hardy, N. M., Yared, J., Rapoport, A. P., Dahiya, et al  
2022; 63 (6): 1339-1347
- **Brexucabtagene autoleucl for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium.**  
Jain, P., Wang, Y., Locke, F. L., Munoz, J., Beitinjaneh, A., Frank, M., Dahiya, S., Jacobs, M. T., Hill, B. T., Lekakis, L. J., Miklos, D., Ghobadi, A., Neelapu, et al  
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucl for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.** *Clinical lymphoma, myeloma & leukemia*  
Jacobs, M. T., Jain, M. D., Gao, F., Nastoupil, L. J., Spiegel, J. Y., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P. M., Oluwole, O. O., McGuirk, J., Deol, et al  
2022
- **Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine.** *Clinical & translational immunology*  
Saharia, K. K., Husson, J. S., Niederhaus, S. V., Iraguha, T., Avila, S. V., Yoo, Y. J., Hardy, N. M., Fan, X., Omili, D., Crane, A., Carrier, A., Xie, W. Y., Vander Mause, et al  
2022; 11 (5): e1391
- **Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review.** *The British journal of ophthalmology*  
Mumtaz, A. A., Fischer, A., Lutfi, F., Matsumoto, L. R., Atanackovic, D., Kolanci, E. T., Hankey, K. G., Hardy, N. M., Yared, J. A., Kocoglu, M. H., Rapoport, A. P., Dahiya, S., Li, et al  
2022
- **Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.** *Blood advances*  
Dahiya, S., Luetkens, T., Lutfi, F., Avila, S., Iraguha, T., Margiotta, P., Hankey, K. G., Lesho, P., Law, J. Y., Lee, S. T., Baddley, J., Kocoglu, M., Yared, et al  
2022; 6 (2): 686-689
- **Deep dissection of the antiviral immune profile of patients with COVID-19.** *Communications biology*  
Atanackovic, D., Avila, S. V., Lutfi, F., de Miguel-Perez, D., Fan, X., Sanchez-Petitto, G., Vander Mause, E., Siglin, J., Baddley, J., Mannuel, H. D., Alkhaldi, H., Hankey, K. G., Lapidus, et al  
2021; 4 (1): 1389
- **Axicabtagene Ciloleucl as Second-Line Therapy for Large B-Cell Lymphoma.** *The New England journal of medicine*  
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M., Kersten, M., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., Munoz, J., Farooq, U., van Meerten, et al  
2021
- **Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucl: Results from the US Lymphoma CAR-T Cell Consortium**  
Spiegel, J. Y., Jain, M. D., Nastoupil, L., Tamaresis, J., Ghobadi, A., Lin, Y., Lekakis, L. J., Reagan, P. M., Oluwole, O. O., McGuirk, J. P., Deol, A., Sehgal, A. R., Goy, et al  
AMER SOC HEMATOLOGY.2021: 3826+

- **Brexucabtagene Autoleucl for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium**  
Wang, Y., Jain, P., Locke, F. L., Munoz, J., Maurer, M. J., Beitinjaneh, A., Frank, M. J., Dahiya, S., McGuirk, J. P., Jacobs, M. T., Goy, A. H., Vose, J. M., Hill, et al  
AMER SOC HEMATOLOGY.2021
- **The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.** *British journal of haematology*  
Lutfi, F., Holtzman, N. G., Kansagra, A. J., Mustafa Ali, M., Bukhari, A., Yan, J., Samanta, S., Gottlieb, D., Kim, D. W., Matsumoto, L. R., Gahres, N., Ruehle, K., Lee, et al  
2021; 195 (3): 405-412
- **Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant.** *Vaccines*  
Atanackovic, D., Luetkens, T., Avila, S. V., Hardy, N. M., Lutfi, F., Sanchez-Petitto, G., Vander Mause, E., Glynn, N., Mannuel, H. D., Alkhalidi, H., Hankey, K., Baddley, J., Dahiya, et al  
2021; 9 (7)
- **Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucl Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Frank, M. J., Hossain, N. M., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., Kirsch, I., Jacob, A. P., Mullins, C. D., Lee, L. W., Kong, K. A., Craig, J., Mackall, et al  
2021: JCO2100377
- **Length of Stay and Hospital Costs for Patients Undergoing Allogeneic Stem-Cell Transplantation.** *JCO oncology practice*  
Godara, A., Siddiqui, N. S., Munigala, S., Dhawan, R., Kansagra, A. J., Rapoport, A. P., Yared, J. A., Dahiya, S.  
2021; 17 (3): e355-e368
- **The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.** *Leukemia research*  
Bergstrom, C. P., Dahiya, S., Chen, W., Zhang, C. C., Zhu, H., Yan, J., Madanat, Y., Patel, P., Vusirkala, M., Ramakrishnan, P., Rizvi, S., Chung, S., Awan, et al  
2021; 100: 106480
- **Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.** *British journal of haematology*  
Lutfi, F., Holtzman, N., Siglin, J., Bukhari, A., Mustafa Ali, M., Kim, D., Sanchez-Petitto, G., Gottlieb, D., Ruehle, K., Hutnick, E., Gahres, N., Hankey, K., Lee, et al  
2021; 192 (1): 212-216
- **Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucl.** *Blood*  
Spiegel, J. Y., Dahiya, S., Jain, M. D., Tamaresis, J. S., Nastoupil, L., Jacobs, M. T., Ghobadi, A., Lin, Y., Lunning, M., Lekakis, L. J., Reagan, P., Oluwole, O. O., McGuirk, et al  
2020
- **Severe dysautonomia as a manifestation of neurotoxicity after CAR-T cell therapy for diffuse large B-cell lymphoma.** *American journal of hematology*  
El Chaer, F., Siegel, A., Holtzman, N. G., Bukhari, A., Lutfi, F., Shah, N. G., Yared, J. A., Rapoport, A. P., McCurdy, M. T., Dahiya, S.  
2020; 95 (6): E146-E148
- **Standard-of-Care Axicabtagene Ciloleucl for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., Oluwole, O., McGuirk, J., Deol, et al  
2020: JCO1902104
- **Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.** *Lancet (London, England)*  
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y. n., Rubinstein, S. M., Rivera, D. R., Shete, S. n., Hsu, C. Y., Desai, A. n., de Lima Lopes, G. n., Grivas, P. n., Painter, C. A., Peters, et al  
2020
- **Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucl in Diffuse Large B-Cell Lymphoma.** *International journal of radiation oncology, biology, physics*  
Sim, A. J., Jain, M. D., Figura, N. B., Chavez, J. C., Shah, B. D., Khimani, F., Lazaryan, A., Krivenko, G., Davila, M. L., Liu, H. D., Falchook, A. D., Dahiya, S., Rapoport, et al  
2019; 105 (5): 1012-1021

- **Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma**  
Frank, M. J., Hossain, N., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., Kirsch, I. M., Jacob, A. P., Mullins, C. D., Lee, L., Kong, K. A., Craig, J., Mackall, et al  
AMER SOC HEMATOLOGY.2019
- **Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium**  
Jain, M. D., Jacobs, M. T., Nastoupil, L. J., Spiegel, J. Y., Feng, G., Lin, Y., Lunning, M. A., Dahiya, S., Lekakis, L. J., Reagan, P. M., Oluwole, O. O., McGuirk, J. P., Deol, et al  
AMER SOC HEMATOLOGY.2019
- **Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium**  
Bennani, N., Maurer, M. J., Nastoupil, L. J., Jain, M. D., Chavez, J. C., Cashen, A. F., Dahiya, S., Lekakis, L. J., Reagan, P. M., Oluwole, O. O., McGuirk, J. P., Deol, A., Sehgal, et al  
AMER SOC HEMATOLOGY.2019
- **Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. *American journal of hematology***  
Bukhari, A., El Chaer, F., Koka, R., Singh, Z., Hutnick, E., Ruehle, K., Lee, S. T., Kocoglu, M. H., Shanholtz, C., Badros, A., Hardy, N., Yared, J., Rapoport, et al  
2019; 94 (10): E273-E275
- **Refractory postallogeic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. *American journal of hematology***  
Bathini, S., Holtzman, N. G., Koka, R., Singh, Z., Wilding, E., Zou, Y., Ruehle, K., Kocoglu, M. H., Badros, A., Hardy, N., Yared, J., Rapoport, A. P., Fontaine, et al  
2019; 94 (8): E216-E219
- **Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.**  
Frank, M., Hossain, N. M., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., Kirsch, I., Jacob, A., Mullins, C. D., Lee, L., Kong, K. A., Craig, J. K., Mackall, et al  
AMER SOC CLINICAL ONCOLOGY.2019
- **Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy *LEUKEMIA & LYMPHOMA***  
Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., Miklos, D. B.  
2019; 60 (2): 503-506
- **Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. *Leukemia & lymphoma***  
Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., Miklos, D. B.  
2018: 1–4
- **Continuing challenges and current issues in acute lymphoblastic leukemia *LEUKEMIA & LYMPHOMA***  
Kansagra, A., Dahiya, S., Litzow, M.  
2018; 59 (3): 526–41
- **Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR-T therapy.**  
Dahiya, S., Le, R., Hossain, N., Abramian, M., Muffly, L. S., Miklos, D.  
AMER SOC CLINICAL ONCOLOGY.2017
- **Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma. *Journal of neuro-oncology***  
Ahluwalia, M. S., Bou-Anak, S., Burgett, M. E., Sarmey, N., Khosla, D., Dahiya, S., Weil, R. J., Bae, E., Huang, P., McGraw, M., Grove, L. M., Olman, M. A., Prayson, et al  
2016
- **Treatment of Cerebral Radiation Necrosis With Bevacizumab: The Cleveland Clinic Experience *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS***  
Sadraei, N. H., Dahiya, S., Chao, S. T., Murphy, E. S., Osei-Boateng, K., Xie, H., Suh, J. H., Peereboom, D. M., Stevens, G. H., Ahluwalia, M. S.  
2015; 38 (3): 304-310
- **Bevacizumab in high-grade gliomas: past, present, and future. *Expert review of anticancer therapy***  
Curry, R. C., Dahiya, S., Alva Venur, V., Raizer, J. J., Ahluwalia, M. S.  
2015; 15 (4): 387-397

- **Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.** *Journal of neuro-oncology*  
Ahluwalia, M. S., Xie, H., Dahiya, S., Hashemi-Sadraei, N., Schiff, D., Fisher, P. G., Chamberlain, M. C., Pannullo, S., Newton, H. B., Brewer, C., Wood, L., Prayson, R., Elson, et al  
2015; 122 (1): 111-119
- **Sleep disturbances in cancer patients: Underrecognized and undertreated** *CLEVELAND CLINIC JOURNAL OF MEDICINE*  
Dahiya, S., Ahluwalia, M. S., Walia, H. K.  
2013; 80 (11): 722-732
- **Recurrent or refractory primary central nervous lymphoma: therapeutic considerations** *EXPERT REVIEW OF ANTICANCER THERAPY*  
Dahiya, S., Murphy, E. S., Chao, S. T., Stevens, G. H., Peereboom, D. M., Ahluwalia, M. S.  
2013; 13 (9): 1109-1119
- **Primary Central Nervous System Lymphoma in the Elderly: The Cleveland Clinic Experience** *ANTICANCER RESEARCH*  
Xie, H., Dahiya, S., Murphy, E. S., Chao, S. T., Suh, J. H., Stevens, G. H., Peereboom, D. M., Ahluwalia, M. S.  
2013; 33 (8): 3251-3258
- **Primary central nervous system posttransplantation lymphoproliferative disorder in an elderly liver transplant recipient.** *Journal of the American Geriatrics Society*  
Dahiya, S., Ooi, W. B., Ahluwalia, M. S., Asik, A.  
2012; 60 (9): 1777-8